HOME >> BIOLOGY >> NEWS
Enzyme studies at Brookhaven Lab may lead to new antiviral agents

UPTON, NY -- Three new enzyme studies at the U.S. Department of Energy's Brookhaven National Laboratory have yielded a new strategy for blocking infection by human adenovirus. The findings, reported in the October, November, and December issues of the journal Biochemistry, have already been used to design novel antiviral drugs.

Adenoviruses cause a number of acute infections, including respiratory and gastrointestinal infections, and also conjunctivitis. In patients with compromised immune systems, such as those infected with human immunodeficiency virus (HIV), an opportunistic adenovirus infection is frequently deadly. "Our new antiviral drugs are expected not only to inhibit adenovirus, but might also be effective against other organisms that use the same enzyme -- including Chlamydia, one of the most prevalent sexually transmitted diseases, and Yersinia pestis, the organism that causes the black plague," said Walter Mangel, the lead scientist on the studies.

During infection, these viruses make an enzyme called a protease, which cleaves or degrades other proteins. The protease is used by the virus to complete the maturation of newly synthesized virus particles. To explain this process, Mangel uses the example of building a cathedral around internal scaffolding. Once the cathedral is in place, the last step is to remove the scaffolding. "Similarly," says Mangel, "adenovirus particles are built with scaffolding protein inside. Once the virus particle is formed, the protease becomes activated and cleaves the scaffolding to render the virus particle infectious."

The three recent Brookhaven studies reveal that the protease is initially synthesized in an inactive form. The inactive enzyme binds to the viral DNA to become partially activated.

"Such activation of a protease by DNA has never been seen before," Mangel said.

The partially activated enzyme then cleaves out a cofactor (a protein fragment), which binds to the protease to
'"/>

Contact: Karen McNulty Walsh
kmcnulty@bnl.gov
631-344-8350
DOE/Brookhaven National Laboratory
4-Dec-2001


Page: 1 2 3

Related biology news :

1. Enzyme maintaining chromosome ends is linked to bone cancer recurrence, decreased survival
2. Enzyme activation appears key in helping internal clock tell night from day
3. Enzyme fully degrades mad cow disease prion
4. Enzyme revealed that is key to funguss ability to breach immune system
5. Enzyme discovery sheds light on causes of rare disease, cancer
6. Enzyme could overcome industrial bleaching waste problems
7. Enzyme controls good cholesterol
8. Enzyme discovery to benefit homeland security, industry
9. Enzyme could aid cancer fight
10. Enzyme once thought harmful to Alzheimers patients now appears key to future treatment
11. Enzyme mimetic reduces tissue damage in colitis animal study

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/22/2019)... (PRWEB) , ... October 21, 2019 , ... Join ... MS, Director of Bioanalytical in a live session on Thursday, October 31, ... CRO partner. , A good CRO partner should have expertise in method development, ...
(Date:10/17/2019)... (PRWEB) , ... October 15, 2019 , ... ... Prepared Media for the Microbiological Community”. , Microbiology International currently manufactures ready-to-use culture ... company also offers pre-poured agar plates & liquid supplements. , This major step ...
(Date:10/15/2019)... ... 2019 , ... Erchonia, the global leader in the manufacturing ... in Orlando & 18th Annual Golf Tournament. The invite-only, four-day event starts ... Melbourne. , The first day will kick off with training and roundtable discussions ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... nQ Medical, Inc. ... School’s 2019 Most Fundable Companies List which was announced at a showcase event yesterday ... million in annual revenue, strong business plans, and impressive near-term growth projections to be ...
(Date:10/22/2019)... N.J. (PRWEB) , ... October 22, 2019 , ... Catalent, ... Clinical Supply Services and Drug Product Technologies Integration, will participate in a panel session ... Conference (HPCLC), to be held at the Gwen Hotel, Chicago, on Oct. 28-30, 2019. ...
(Date:10/22/2019)... LOS ANGELES (PRWEB) , ... October 22, 2019 ... ... software provider, today announced integration of the Alertus Mass Notification System into its ... critical infrastructure to the Enplug platform, making it possible for users to leverage ...
(Date:10/22/2019)... ... , ... DermBiont, a clinical stage microbiome biotechnology company developing ... safety endpoints, with no application site reactions and no adverse events, in a ... tinea pedis (athlete’s foot). Additionally, the trial demonstrated a clinical response with improvement ...
Breaking Biology Technology:
Cached News: